PA-FUJIREBIO
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes.
“In 2023 we already introduced two new important neuro assays for RUO-based detection of Neurofilament Light (NfL) and pTau 217,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.”
The Lumipulse G GFAP assay will allow the scientific community and clinical research professionals to further study and understand the potential clinical utility of this promising astrocytic biomarker for neurological conditions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and brain-related acute traumatic injuries or stroke.1
With the fully automated random-access LUMIPULSE G platform, professionals will be able to measure GFAP in a user-friendly and reliable way. This standardized immunoassay platform is already widely available in labs for routine and research testing of neurological disease-related biomarkers. The new assay meets the necessary quality, throughput, and regulatory requirements to support potential routine testing of GFAP in combination with other tests from the Fujirebio neuro biomarker menu.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in high-quality in vitro diagnostics (IVD) testing with more than 50 years’ accumulated experience in the research, development, production and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/neuro.
References:
- Abdelhak, A., Foschi, M., Abu-Rumeileh, S. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18, 158–172 (2022). https://doi.org/10.1038/s41582-021-00616-3
* Please contact your local Fujirebio representative for the availability of this product in your country
Lumipulse is a registered trademark of Fujirebio Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240726266467/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estée Lauder Announces Actress Daisy Edgar-Jones as Newest Global Brand Ambassador8.1.2026 14:00:00 CET | Press release
Estée Lauder today announced that it has signed acclaimed British actress, Daisy Edgar-Jones, as its newest Global Brand Ambassador. Daisy will represent Estée Lauder skin care, makeup, and fragrance, with her first campaign debuting on February 2nd across print, digital and in-store. She joins Estée Lauder’s current roster of global talent including Ana de Armas, Bianca Brandolini, Carolyn Murphy, Imaan Hammam, IU, Karlie Kloss, Paulina Porizkova and Yang Mi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108459289/en/ Daisy Edgar-Jones for Estée Lauder “As an actress, I love how makeup can tell a story of who we are. I have always admired how Estée Lauder celebrates confidence and individuality in women. The legacy, elegance, and strength of the brand is so inspiring,” said Daisy Edgar-Jones. “It feels surreal to be part of the Estée Lauder family – and it truly feels like a family.” “Daisy is very much the breakout sta
Kinaxis Appoints Razat Gaurav as New CEO8.1.2026 14:00:00 CET | Press release
With over two decades of supply chain experience and a proven record of driving global growth Razat Gaurav is uniquely positioned to lead Kinaxis in its next phase of AI-driven innovation. Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/ Razat Gaurav, Kinaxis CEO “After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forw
Liberty Latin America Expands Exclusive International Voice Managed Services Partnership with BTS to 22 Additional Caribbean Markets8.1.2026 13:30:00 CET | Press release
BTS, the leading provider, technology enabler, and trusted partner to CommTech players worldwide, has been appointed by Liberty Latin America (LLA) as the exclusive provider of International Voice Managed Services for 22 additional Caribbean markets. This expansion builds on the successful 2023 partnership, in which BTS was selected as the exclusive international voice provider for Costa Rica, Panama, Puerto Rico, and the U.S. Virgin Islands. With this agreement, BTS will now support International Long Distance (ILD) services across a total of 26 LLA markets. Effective January 1, 2026, BTS began handling ILD voice services for the newly added Caribbean markets, enabling greater service consistency, enhanced quality, and improved operational efficiency across LLA’s regional footprint. The 22 new markets incorporated under the expanded partnership include: Anguilla, Antigua, Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman, Curaçao, Dominica, Grenada, Jamaica, Montserrat, Saba,
Det-Tronics Acquires Optronics8.1.2026 13:28:00 CET | Press release
Optronics is a global leader in optical gas detection products and solutions for high-hazard, mission-critical applications Det-Tronics, a global leader in fire and gas safety systems, has acquired Optronics, a Norway-based company that specializes in optical gas detection technologies. Det-Tronics is part of Spectrum Safety Solutions that is based in Stamford, CT. Optronics, founded in 2018, is a technology leader in high-end optical gas detection products and solutions for energy, marine and industrial applications. Optronics has a strong record of innovation, bringing leading products and expert solutions to market for its customers. (www.optronics-technology.com) “Det-Tronics’ strategy is built on growth, innovation and quality. Optronics and Det-Tronics are a perfect fit to grow our businesses, drive new innovations and lead the market with high quality and reliable products and solutions,” noted Johannes Mario Kahlert, President of Det-Tronics. “We are very excited for the path a
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 13:00:00 CET | Press release
V-212 was well tolerated and demonstrated an excellent safety profileRobust IgG responses were observed to all three antigens in the vaccineResults support further development of V-212 independently and in combination with approved pneumococcal conjugate vaccines (PCVs) Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom